Anzeige
Mehr »
Login
Sonntag, 09.02.2025 Börsentäglich über 12.000 News von 685 internationalen Medien
Eilmeldung: Trumps Zölle katapultieren Gold in die Höhe - Brasilianische Gold-Story könnte zur wahren Goldgrube werden!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3C4HE | ISIN: US29415J1060 | Ticker-Symbol: 5HJ
Frankfurt
07.02.25
08:05 Uhr
2,940 Euro
-0,080
-2,65 %
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
ENVVENO MEDICAL CORPORATION Chart 1 Jahr
5-Tage-Chart
ENVVENO MEDICAL CORPORATION 5-Tage-Chart
RealtimeGeldBriefZeit
2,9203,02007.02.

Aktuelle News zur ENVVENO MEDICAL Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
ENVVENO MEDICAL Aktie jetzt für 0€ handeln
FrenVVeno Medical Corporation: Interim Two-Year Follow-Up Data from the VenoValve U.S. Pivotal Trial to be Presented Today at the VESS 2025 Annual Winter Meeting200 Two-year follow-up data from 34 subjects in the VenoValve pivotal trial show sustained clinical improvement and continued patient benefit, from 12 months to 24 months.78% of subjects maintained a clinically...
► Artikel lesen
03.01.Envveno Medical-Direktor Duhay Francis kauft Aktien im Wert von 249.999 US-Dollar2
03.01.Insider Buying: enVVeno Medical Corporation (NASDAQ:NVNO) Director Acquires 3,500 Shares of Stock3
02.01.enVVeno Medical Corporation (NASDAQ:NVNO) Director Robert Gray Buys 3,500 Shares2
26.12.24Envveno Medical: Direktor Sanjay Shrivastava erwirbt Aktien im Wert von 15.660 US-Dollar-
23.12.24EnVVeno Medical-Direktor Matthew Jenusaitis erwirbt Aktien im Wert von 24.338 US-Dollar1
20.12.24NVNO stock touches 52-week low at $2.5 amid market challenges1
20.12.24NVNO-Aktie erreicht 52-Wochen-Tief bei 2,5 US-Dollar1
16.12.24enVVeno Medical Corporation: enVVeno Medical Successfully Completes Final Wave of Implants in Pre-Clinical GLP Study for enVVe148Successful Completion of All Planned Implants in GLP StudyenVVe Delivery System Demonstrates Consistent PerformanceCompany Maintains Timeline for IDE Application Submission by Mid-2025, Pending GLP...
► Artikel lesen
12.12.24NVNO Stock Touches 52-Week Low at $2.9 Amid Market Challenges1
12.12.24NVNO-Aktie erreicht 52-Wochen-Tief bei 2,9 US-Dollar1
03.12.24NVNO Stock Touches 52-Week Low at $3.01 Amid Market Challenges1
03.12.24NVNO-Aktie erreicht 52-Wochen-Tief bei 3,01 US-Dollar1
27.11.24enVVeno Medical Corporation: enVVeno Medical Highlights Successful 2024 VEITH Symposium with Launch of Recap Website225Interviews with participating patients from the VenoValve® U.S. Pivotal TrialWebcast replay from with the presenting Primary InvestigatorsPresentation with data from the VenoValve U.S. Pivotal TrialAccess...
► Artikel lesen
25.11.24NVNO Completes Application for VenoValve's PMA, Shares Likely to Gain2
20.11.24enVVeno Medical Corporation: enVVeno Medical to Present Definitive One Year Data from the VenoValve U.S. Pivotal Trial Today at the 51st Annual VEITH Symposium19985% Clinical Meaningful Benefit Responder Rate7.91 Point Average rVCSS Improvement for the Clinically Meaningful Benefit Responder Cohort75% Median Reduction in Pain (VAS)87% Median Ulcer Area Reduction97%...
► Artikel lesen
19.11.24enVVeno Medical strebt FDA-Zulassung für VenoValve an3
19.11.24enVVeno Medical Corporation: enVVeno Medical Submits the VenoValve PMA Application Seeking FDA Approval463Definitive One Year Data from PMA Application to be Presented Wednesday at 51st Annual VEITH SymposiumCompany to Host a Conference Call with the PIs Presenting the Pivotal Trial Data on Wednesday, November...
► Artikel lesen
19.11.24enVVeno Medical seeks FDA approval for VenoValve2
31.10.24enVVeno Medical Corporation: enVVeno Medical Reports Third Quarter 2024 Financial Results and Confirms Guidance for Release of Definitive VenoValve Data in November and Completion of FDA Premarket Approval Application for VenoValve in Q4 of this Year182Continued progress toward submission of 5th and final module of FDA premarket approval (PMA) application for VenoValve® in Q4GLP study for enVVe® transcatheter-based replacement venous valve underway...
► Artikel lesen
Seite:  Weiter >>
48 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1